Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Comparing the Bowel Cleansing Efficacy of PLENVU® Versus SELG-ESSE® Using a 2-Day Split Dosing Regimen.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03742232
Recruitment Status : Recruiting
First Posted : November 15, 2018
Last Update Posted : September 10, 2019
Sponsor:
Information provided by (Responsible Party):
Istituto Clinico Humanitas

Brief Summary:
This study is a multicentre randomized parallel group phase IV study comparing the bowel cleansing efficacy, safety and tolerability of PLENVU® (a 1 litre PEG Bowel Cleansing Solution) versus SELG-ESSE® (a 4 litre PEG Bowel Cleansing Solution) using a 2-Day Split Dosing Regimen.

Condition or disease Intervention/treatment Phase
Colon Polyp Colon Adenoma Colon Lesion Drug: PEG3350 Drug: Macrogol 4000 Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Diagnostic
Official Title: A Multicentre Randomized Parallel Group Phase IV Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of PLENVU® Versus SELG-ESSE® Using a 2-Day Split Dosing Regimen.
Actual Study Start Date : October 31, 2018
Estimated Primary Completion Date : October 2019
Estimated Study Completion Date : November 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: PLENVU
PLENVU® supplied as two powder-for-oral-solution formulations. One formulation contains PEG3350, sodium sulphate and electrolytes, and the second formulation contains PEG3350, sodium ascorbate, ascorbic acid, and electrolytes.
Drug: PEG3350

PLENVU® supplied as two powder-for-oral-solution formulations. One formulation contains PEG3350, sodium sulphate and electrolytes, and the second formulation contains PEG3350, sodium ascorbate, ascorbic acid, and electrolytes.

PLENVU® Administration: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy).


Active Comparator: SELG-ESSE
SELG-ESSE® supplied as powder-for-oral-solution containing PEG4000, simethicone, sodium sulphate and sodium bicarbonate, and electrolytes.
Drug: Macrogol 4000

SELG-ESSE® supplied as powder-for-oral-solution containing PEG4000, simethicone, sodium sulphate and sodium bicarbonate, and electrolytes.

SELG-ESSE® Administration: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy).





Primary Outcome Measures :
  1. Bowel cleansing efficacy [ Time Frame: 1 Day of colonoscopy ]
    To evaluate the overall bowel cleansing efficacy of 2-day split-dosing with PLENVU compared to a 2-day split-dosing regimen with SELG-ESSE®, graded according to the Boston Bowel Preparation Scale (BBPS) in patients undergoing screening, surveillance or diagnostic colonoscopy.


Secondary Outcome Measures :
  1. Polip Detection Rate [ Time Frame: 1 Day of colonoscopy ]
    To assess the overall Polip Detection Rate with PLENVU compared to SELG-ESSE

  2. Adenoma Detection Rate [ Time Frame: 1 Day of colonoscopy ]
    To assess the overall Adenoma Detection Rate with PLENVU compared to SELG-ESSE;

  3. Adverse events [ Time Frame: 4 days after colonscopy ]
    To assess the incidence of adverse events in PLENVU group comparing SELG-ESSE arm



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients must provide written informed consent.
  2. Male and female outpatients and inpatients aged: ≥18 to ≤85 years undergoing a screening, surveillance or diagnostic colonoscopy.
  3. Females of child-bearing potential must have a negative pregnancy test at Screening and at Visit 2 and must be practising one of the following methods of birth control and agree to continue with the regimen throughout the study period:

    • Oral, implantable, or injectable contraceptives (for a minimum of three months before study entry) in combination with a condom;
    • Intrauterine device in combination with a condom; Double barrier method (condom*, and occlusive cap [diaphragm or cervical/vault caps] with spermicidal foam/gel/film/ cream/suppository); *A female condom and a male condom should not be used together as friction between the two can result in either product failing.

    If any female patient has a positive pregnancy test at Visit 2, they will be excluded from further participation in the study for the efficacy evaluation, i.e. they will not undergo the colonoscopy procedure. The Investigator will be required to arrange a colonoscopy procedure outside of the study.

    Note: The above birth control methods do not apply to females who are postmenopausal or surgically sterile i.e. 12 months of natural (spontaneous) amenorrhea or 6 weeks' post-surgical bilateral oophorectomy with or without hysterectomy or hysterectomy, or whose sole sexual partner has had a vasectomy and has received medical assessment of the surgical success.

  4. Willing, able and competent to complete the entire study and to comply with instructions.

Exclusion Criteria:

  1. Patients with past history within last 12 months or current episode of severe constipation (requiring repeated use of laxatives/enema or physical intervention before resolution), known or suspected ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis or megacolon.
  2. Patients with ongoing severe acute Inflammatory Bowel Disease (IBD).
  3. Patients who have had previous significant gastrointestinal surgeries, including colonic resection, sub-total colectomy, abdomino-perineal resection, de-functioning colostomy, Hartmann's procedure and defunctioning ileostomy or other similar surgeries involving structure and function of the small or large colon.
  4. Regular use of laxatives or colon motility altering drugs (i.e. more than 2-3 times per week) in the last 28 days prior to the Screening Visit and/or laxative use within 72 hours prior to administration of the preparation.
  5. Patients with active intestinal bleeding episodes
  6. Known glucose-6-phosphate dehydrogenase (G6PD) deficiency.
  7. Known phenylketonuria.
  8. Known hypersensitivity to polyethylene glycols, ascorbic acid and sulfates (not including sulfa-based products) or any other component of the investigational product or comparator.
  9. Past history within the last 12 months or evidence of any on-going clinically relevant electrocardiogram (ECG) abnormalities (e.g. arrhythmias).
  10. History of uncontrolled hypertension with systolic blood pressure >170 mmHg and diastolic blood pressure >100 mmHg.
  11. Patients with cardiac insufficiency NYHA grades III or IV.
  12. Patients with severe renal insufficiency.
  13. Patients with known liver disease of grades B and C according to the Child Pugh classification.
  14. Patients suffering from dehydration at screening as evaluated by the Investigator from physical examination.
  15. Patients with pre-existing clinically significant electrolyte abnormalities, or dehydration.
  16. Patients with impaired consciousness that might predispose them to pulmonary aspiration.
  17. Patients undergoing colonoscopy for foreign body removal and/or decompression.
  18. Patients who are pregnant or lactating, or intending to become pregnant during the study.
  19. Clinically relevant findings on physical examination based on the Investigator's judgment.
  20. History of drug or alcohol abuse within the 12 months prior to dosing.
  21. Concurrent participation in an investigational drug or device study or participation within three months of study entry.
  22. Patients who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures, e.g. cognitively impaired, debilitated or fragile patients.
  23. Patients who are ordered to live in an institution on court or authority order.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03742232


Locations
Layout table for location information
Italy
Centro di Riferimento Oncologico Recruiting
Aviano, Italia, Italy
Contact: Renato Cannizzaro    +39 0434 65928    rcannizzaro@cro.it   
Principal Investigator: Renato Cannizzaro         
Sub-Investigator: Stefania Maiero         
Sub-Investigator: Mara Fornasarig         
Sub-Investigator: Giovanni Guarnieri         
Fondazione Poliambulanza Recruiting
Brescia, Italia, Italy
Contact: Cristiano Spada    0039-030/3515372    cristiano.spada@poliambulanza.it   
Principal Investigator: Cristiano Spada         
Sub-Investigator: Paola Cesaro         
Sub-Investigator: Sebastian M Miluzzo         
Sub-Investigator: Stefania Piccirelli         
Nuovo Regina Margherita Hospital Recruiting
Roma, Italia, Italy
Contact: Cesare Hassan    06 7730 7215    cesareh@hotmail.com   
Principal Investigator: Cesare Hassan         
Sub-Investigator: Sabrina Berardi         
Principal Investigator: Luisa Gallucci         
ISMETT Completed
Palermo, Italy
Humanitas Research Hospital Completed
Rozzano, Italy, 20089
Sponsors and Collaborators
Istituto Clinico Humanitas

Layout table for additonal information
Responsible Party: Istituto Clinico Humanitas
ClinicalTrials.gov Identifier: NCT03742232     History of Changes
Other Study ID Numbers: 2063
First Posted: November 15, 2018    Key Record Dates
Last Update Posted: September 10, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Adenoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Polyethylene glycol 3350
Sodium sulfate
Pharmaceutical Solutions
Laxatives
Gastrointestinal Agents
Cathartics